Last reviewed · How we verify
HB-101 vaccine
HB-101 vaccine is a Biologic drug developed by Hookipa Biotech GmbH. It is currently in Phase 2 development.
At a glance
| Generic name | HB-101 vaccine |
|---|---|
| Sponsor | Hookipa Biotech GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients (PHASE2)
- Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HB-101 vaccine CI brief — competitive landscape report
- HB-101 vaccine updates RSS · CI watch RSS
- Hookipa Biotech GmbH portfolio CI
Frequently asked questions about HB-101 vaccine
What is HB-101 vaccine?
HB-101 vaccine is a Biologic drug developed by Hookipa Biotech GmbH.
Who makes HB-101 vaccine?
HB-101 vaccine is developed by Hookipa Biotech GmbH (see full Hookipa Biotech GmbH pipeline at /company/hookipa-biotech-gmbh).
What development phase is HB-101 vaccine in?
HB-101 vaccine is in Phase 2.
Related
- Manufacturer: Hookipa Biotech GmbH — full pipeline
- Compare: HB-101 vaccine vs similar drugs
- Pricing: HB-101 vaccine cost, discount & access